Study: CBN and THCV Effective in Reducing Alcohol Intake, Outperforming CBD
Cannabinoids alcohol use disorder research highlights the potential of CBN and THCV in reducing alcohol consumption. These cannabinoids outperform CBD in preclinical models. Further human trials are needed to confirm these findings.
Higher Risk Cannabis Use Indicators Among People Living in Canada: A Cross-Sectional Study
This study focuses on cannabis use disorder risk assessment among people living in Canada. It identifies key indicators of problematic cannabis use to aid clinical screening. Understanding these risk factors helps improve population health strategies.
Does Cannabis Reduce Alcohol Consumption? A New Study Weighs In
Cannabis alcohol substitution therapy is an emerging approach in addiction medicine with high clinical relevance. This therapy explores whether cannabis use can reduce alcohol consumption. Understanding this substitution effect is crucial for effective…
22News InFocus: Gambling and Cannabis Laws in Massachusetts
Massachusetts cannabis gambling regulation is a growing public health focus in 2026. Clinicians must understand how these laws affect medical cannabis access and gambling addiction prevention. Policy changes may influence patient care and regulatory…
Smoked Cannabis and Alcohol Use Disorder: Controlled Trial Findings
This study on cannabis alcohol use disorder treatment shows smoked cannabis reduces immediate alcohol consumption in a controlled trial. The findings suggest cannabis may offer harm reduction benefits for alcohol use disorder. Clinicians should consider…
Texas to Conduct Its Own Ibogaine Clinical Trials – Clinical Insights
Texas ibogaine clinical trials mark a pivotal step in state-level psychedelic research. These trials focus on addiction treatment potential while addressing cardiac safety concerns. This initiative highlights Texas's leadership in advancing alternative…
Texas Launches State-Sponsored Psychedelic Research with Ibogaine Trials
Texas is pioneering state-sponsored psychedelic research by initiating ibogaine clinical trials for addiction treatment. This approach represents a significant shift in regulatory pathways at the state level. State-sponsored psychedelic research could…
Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook
Aelis Farma announced its financial results for 2025, highlighting progress in cannabis use disorder treatment development. The 2026 outlook confirms continued clinical trial advancements. This report focuses on Aelis Farma financial results 2025 and…
Relationally anchored motivation in alcohol and cannabis use disorder: a clinical case analysis
This case analysis highlights relational motivation substance use recovery in patients with co-occurring alcohol and cannabis use disorders. Interpersonal relationships serve as key motivational anchors supporting recovery efforts. Understanding these…
Stellate Ganglion Block for Cannabis Use Disorder: Case Series Insights
This case series explores stellate ganglion block cannabis use disorder as a novel procedural intervention. It highlights the potential of sympathetic nervous system modulation in managing cannabis dependence. The findings represent early-stage research…
